Compare Adaptive Biotechnologies Corp (ADPT) vs Invesco DB Oil Fund (DBO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Invesco DB Oil Fund — how do they compare? Adaptive Biotechnologies Corp trades at $20.07 (market cap $3.33B), while Invesco DB Oil Fund trades at $18.59. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Invesco DB Oil Fund nearer its low. Which is the better fit depends on your goals.
| ADPT | DBO | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Commodities - Energy |
52-Week High | $22.37 | $23.80 |
52-Week Low | $10.24 | $11.98 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
DBO trades at $17.34 with a modest 0.35% daily gain amid bearish technical signals. The stock shows mixed momentum with oversold RSI readings but faces strong resistance at $18. Recent oil price volatility driven by Middle East tensions and supply disruptions creates both opportunities and risks for energy sector stocks.
The outlook remains cautious with technical indicators favoring bearish momentum, though oversold conditions suggest potential for near-term stabilization. Investment opportunity exists if geopolitical tensions sustain higher oil prices, but risks include supply growth and demand uncertainty that could pressure energy stocks further.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Invesco DB Oil Fund
DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →
